Skip to Content

Ninlaro Approval History

Ninlaro (ixazomib) is an oral proteasome inhibitor indicated for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Development History and FDA Approval Process for Ninlaro

Nov 20, 2015Approval FDA Approves Ninlaro (ixazomib) for Multiple Myeloma
Sep  9, 2015U.S. FDA Grants Priority Review to Takeda's Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Jul 15, 2015Takeda Submits NDA for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
May 12, 2015Takeda Announces First Patient Enrolled in Global Phase 3 Study of Ixazomib as Maintenance Therapy for Newly Diagnosed Multiple Myeloma
Feb 10, 2015Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Multiple Myeloma Met Primary Endpoint
Dec  7, 2014Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma
Dec  1, 2014Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.